Tribe Capital Growth Corp I
ATVCW
NASDAQ Capital Market0.12
USD
+0.01
- -
Tribe Capital Growth Corp I
ATVCW
(NASDAQ Capital Market)
Recent
price
0.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tribe Capital Growth Corp I (ATVCW) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary business is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, targeting technology-led companies in emerging markets, the United States, and Asia (excluding China and Hong Kong); it offers no operating products or services beyond this structure, including redeemable units comprising Class A common stock and warrants exercisable at $11.50 per share, private placement warrants, and founder shares held by its sponsor. Founded in 2020 and headquartered at 2700 19th Street, San Francisco, California, the company completed its initial public offering in March 2021, raising $276 million through 27.6 million units at $10 each, with concurrent private placement of 5.013 million warrants generating $7.52 million; funds are held in a trust account invested in U.S. government securities or money market funds, subject to redemptions by public stockholders. In July 2022, Tribe Capital withdrew as co-sponsor, prompting a name change to Iris Acquisition Corp, full management overhaul—including resignations of CEO Arjun Sethi, CFO Omar Chohan, and others—strategic shift to prioritize emerging markets, and relocation of principal executive offices to George Town, Grand Cayman; multiple charter amendments extended its combination deadline through March 2025, accompanied by substantial redemptions reducing trust assets to approximately $2 million as of late 2024, with a pending business combination with Liminatus Pharma, LLC approved by stockholders in March 2025 but facing further redemptions and promissory notes to related parties.